Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy
Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy
复制标题
DOI：
10.1016/j.jhep.2018.09.029
复制
发表时间：
2019-01-01
影响因子：
25.7
通讯作者：
Koike, Kazuhiko
中科院分区：
文献类型：
--
作者：
Kinoshita, Mizuki Nishibatake;Minami, Tatsuya;Koike, Kazuhiko
背景和目标：直接作用抗病毒药物（DAA）是否加速丙型肝炎相关肝细胞癌（HCC）治愈治疗后的复发仍存在争议。本研究的目的是评估肝癌复发后DAA治疗慢性丙型肝炎。方法：我们招募的患者成功的射频消融治疗丙型肝炎相关的肝癌的历史，接受抗病毒治疗DAA（DAA组：147例）或干扰素（IFN）为基础的治疗（IFN组：156例）。我们使用Kaplan-Meier方法评估了抗病毒治疗开始后的HCC复发率，并通过多变量考克斯比例风险回归分析评估了HCC复发的危险因素。复发模式分类如下：单肿瘤肝内复发
Background & Aims: It remains controversial whether direct-acting antivirals (DAAs) accelerate the recurrence of hepatitis C-related hepatocellular carcinoma (HCC) after curative therapy. This study aimed to evaluate HCC recurrence after DAA treatment of chronic hepatitis C.Methods: We enrolled patients with a history of successful radiofrequency ablation treatment for hepatitis C-related HCC who received antiviral therapy with DAAs (DAA group: 147 patients) or with interferon (IFN)-based therapy (IFN group: 156 patients). We assessed HCC recurrence rates from the initiation of antiviral therapy using the Kaplan-Meier method and evaluated risk factors for HCC recurrence by multivariate Cox proportional hazard regression analysis. The recurrence pattern was categorized as follows: intrahepatic recurrence with a single tumor